Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors

Cardiovascular Research

Volumn 83, Issue 3, 2009, Pages 595-603

  Rodríguez, Cristina ^a   Alcudia, Javier F ^a   Martínez González, José ^a   Guadall, Anna ^a   Raposo, Berta ^a   Sánchez Gómez, Sonia ^a   Badimon, Lina ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Atherosclerosis; Endothelial function; Lysyl oxidase; Porcine model; Statins

Indexed keywords

ATORVASTATIN; FARNESOL; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; PRAVASTATIN; PROTEIN KINASE C; PROTEIN LYSINE 6 OXIDASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CATTLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE;

ANIMALS; ATHEROSCLEROSIS; CAPILLARY PERMEABILITY; CATTLE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOTHELIAL CELLS; FARNESOL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN-LYSINE 6-OXIDASE; PYRROLES; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; RISK FACTORS; RNA, MESSENGER; SIMVASTATIN; SWINE; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651124960     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp136     Document Type: Article

References (66)

1. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-1131.
2. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003;93:e98-e103.
3. Martínez-González J. Molecular mechanisms underlying the lipid-independent effects of statins: clinical relevance. Basic Clin Pharmacol Toxicol 2006;99:10-12.
4. Martínez-González J, Badimon L. Influence of statin use on endothelial function: from bench to clinics. Curr Pharm Des 2007;13:1771-1786.
5. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V et al. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem 2007;14:243-248.
6. Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001;21:122-128.
7. Baetta R, Camera M, Comparato C, Altana C, Ezekowitz MD, Tremoli E. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2002;22:692-698.
8. Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol 2002; 22:1832-1837.
9. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684-691.
10. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-121.
11. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004;35:2708-2711.
12. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003;88:660- 672.
13. Rodríguez C, Martínez-González J, Raposo B, Alcudia JF, Guadall A, Badimon L. Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases. Cardiovasc Res 2008;79:7-13.
14. Song YL, Ford JW, Gordon D, Shanley CJ. Regulation of lysyl oxidase by interferon-g in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:982-988.
15. Mäki J, Räsänen J, Tikkanen H, Sormunen R, Mäkikallio K, Kivirikko K et al. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction and perinatal death in mice. Circulation 2002;106:2503-2509.
16. Hornstra IK, Birge S, Starcher B, Bailey AJ, Mecham RP, Shapiro SD. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J Biol Chem 2003;278:14387-14393.
17. Rodriguez C, Raposo B, Martinez-Gonzalez J, Casani L, Badimon L. Low density lipoproteins downregulate lysyl oxidase in vascular endothelial cells and the arterial wall. Arterioscler Thromb Vasc Biol 2002;22: 1409-1414.
18. Raposo B, Rodriguez C, Martinez-Gonzalez J, Badimon L. High levels of homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in vascular endothelial cells. Atherosclerosis 2004;177:1-8.
19. Rodríguez C, Alcudia JF, Martínez-González J, Raposo B, Navarro MA, Badimon L. Lysyl oxidase (LOX) down-regulation by TNFalpha: a new mechanism underlying TNFalpha-induced endothelial dysfunction. Atherosclerosis 2008;196:558-564.
20. Alcudia JF, Martinez-Gonzalez J, Guadall A, Gonzalez-Diez M, Badimon L, Rodriguez C. Lysyl oxidase and endothelial dysfunction: mechanisms of lysyl oxidase down-regulation by pro-inflammatory cytokines. Front Biosci 2008;13:2721-2727.
21. Rodriguez C, Martinez-Gonzalez J, Sanchez-Gomez S, Badimon L. LDL downregulates CYP51 in porcine vascular endothelial cells and in the arterial wall through a sterol regulatory element binding protein-2-dependent mechanism. Circ Res 2001;88:268-274.
22. Rodriguez C, Raposo B, Martinez-Gonzalez J, Llorente-Cortes V, Vilahur G, Badimon L. Modulation of ERG25 expression by LDL in vascular cells. Cardiovasc Res 2003;58:178-185.
23. Martínez-González J, Raposo B, Rodríguez C, Badimon L. 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 2001;21:804-809.
24. Garcia-Ramirez M, Martinez-Gonzalez J, Juan-Babot JO, Rodriguez C, Badimon L. Transcription factor SOX18 is expressed in human coronary atherosclerotic lesions and regulates DNA synthesis and vascular cell growth. Arterioscler Thromb Vasc Biol 2005;25:2398-2403.
25. Martinez-Gonzalez J, Escudero I, Badimon L. Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL. Atherosclerosis 2004;174:305-313.
26. Casani L, Sanchez-Gomez S, Vilahur G, Badimon L. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost 2005;94:1035-1041.
27. Martínez-González J, Berrozpe M, Varela O, Badimon L. Heterogeneity of smooth muscle cells in advanced human atherosclerotic plaques: intimal smooth muscle cells expressing a fibroblast surface protein are highly activated by platelet-released products. Eur J Clin Invest 2001;31: 939-949.
28. Hippenstiel S, Kratz T, Krull M, Seybold J, von Eichel-Streiber C, Suttorp N. Rho protein inhibition blocks protein kinase C translocation and activation. Biochem Biophys Res Commun 1998;245:830-834.
29. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
30. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endotheliumdependent coronary vasomotion. N Engl J Med 1995;332:488-493.
31. Alonso R, Mata P, De Andres R, Villacastin BP, Martinez-Gonzalez J, Badimon L. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis 2001;157:423-429.
32. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell 2004;116: 167-179.
33. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007;115:1789-1797.
34. Shanley CJ, Gharaee-Kermani M, Sarkar R, Welling TH, Kriegel A, Ford JW et al. Transforming growth factor-beta 1 increases lysyl oxidase enzyme activity and mRNA in rat aortic smooth muscle cells. J Vasc Surg 1997;25: 446-452.
35. Ferro T, Neumann P, Gertzberg N, Clements R, Johnson A. Protein kinase C-alpha mediates endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell Mol Physiol 2000;278:L1107-L1117.
36. Ross D, Joyner WL. Resting distribution and stimulated translocation of protein kinase C isoforms alpha, epsilon and zeta in response to bradykinin and TNF in human endothelial cells. Endothelium 1997;5:321-332.
37. Koss M, Pfeiffer GR 2nd, Wang Y, Thomas ST, Yerukhimovich M, Gaarde WA et al. Ezrin/radixin/moesin proteins are phosphorylated by TNF-alpha and modulate permeability increases in human pulmonary microvascular endothelial cells. J Immunol 2006;176:1218-1227.
38. Tinsley JH, Hunter FA, Childs EW. PKC and MLCK-dependent, cytokine-induced rat coronary endothelial dysfunction. J Surg Res 2009;152:76-83.
39. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rhokinase). J Biol Chem 1996;271:20246-20249.
40. Petrache I, Verin AD, Crow MT, Birukova A, Liu F, Garcia JG. Differential effect of MLC kinase in TNF-alpha-induced endothelial cell apoptosis and barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2001;280: L1168-L1178.
41. Nwariaku FE, Rothenbach P, Liu Z, Zhu X, Turnage RH, Terada LS. Rho inhibition decreases TNF-induced endothelial MAPK activation and monolayer permeability. J Appl Physiol 2003;95:1889-1895.
42. McKenzie JA, Ridley AJ. Roles of Rho/ROCK and MLCK in TNF-alpha-induced changes in endothelial morphology and permeability. J Cell Physiol 2007;213:221-228.
43. Campos S, Ashworth SL, Wean S, Hosford M, Sandoval R, Hallett MA et al. Cytokine induced F-actin reorganization in endothelial cells involves RhoA activation. Am J Physiol Renal Physiol 2009;296:F487-F495.
44. Stamatovic SM, Dimitrijevic OB, Keep RF, Andjelkovic AV. Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J Biol Chem 2006;281:8379-8388.
45. SatpathyM,Gallagher P, Lizotte-Waniewski M,Srinivas SP. Thrombin-induced phosphorylation of the regulatory light chain of myosin II in cultured bovine corneal endothelial cells. Exp Eye Res 2004;79:477-486.
46. Barandier C, Ming XF, Rusconi S, Yang Z. PKC is required for activation of ROCK by RhoA in human endothelial cells. Biochem Biophys Res Comm 2003;304:714-719.
47. Fujino H, Regan JW. Prostaglandin F2alpha amplifies tumor necrosis factor-alpha promoter activity by the FPB prostanoid receptor. Biochem Biophys Res Comm 2004;317:1114-1120.
48. Saijonmaa O, Nyman T, Stewen P, Fyhrquist F. Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol 2004;286:H2096-H2102.
49. Shiga N, Hirano K, Hirano M, Nishimura J, Nawata H, Kanaide H. Longterm inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery. Circ Res 2005;96:1014-1021.
50. Laufs U, Liao JK. Related post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273:24266-24271.
51. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 87:616-622.
52. Cammarano MS, Minden A. Dbl and the Rho GTPases activate NF kappa B by I kappa B kinase (IKK)-dependent and IKK-independent pathways. J Biol Chem 2001;276:25876-25882.
53. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 2002;277:15309- 15316.
54. Tramontano AF, O'Leary J, Black AD, Muniyappa R, Cutaia MV, El-Sherif N. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun 2004;320:34-38.
55. Essler M, Retzer M, Bauer M, Heemskerk JW, Aepfelbacher M, Siess W. Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J Biol Chem 1999;274:30361-30364.
56. Zhu Y, Liao HL, Niu XL, Yuan Y, Lin T, Verna L et al. Low density lipoprotein induces eNOS translocation to membrane caveolae: the role of RhoA activation and stress fiber formation. Biochim Biophys Acta 2003;1635: 117-126.
57. van Nieuw Amerongen GP, Vermeer MA, Nègre-Aminou P, Lankelma J, Emeis JJ, van Hinsbergh VWM. Simvastatin improves disturbed endothelial barrier function. Circulation 2000;102:2803-2809.
58. Zeng L, Xu H, Chew TL, Eng E, Sadeghi MM, Adler S et al. HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J 2005;19:1845-1847.
59. Wilson SH, Herrmann J, Lerman LO, Holmes DR Jr, Napoli C, Ritman EL et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002;105:415-418.
60. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-428.
61. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004;177:161-166.
62. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-587.
63. Martínez-González J, Alfón J, Berrozpe M, Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001;159:27-33.
64. Sen-Banerjee S, Mir S, Lin Z, Hamik A, Atkins GB, Das H et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005;112:720-726.
65. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:58-63.
66. Crespo J, Martínez-González J, Rius J, Badimon L. Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res 2005;67:333-341.